Results 91 to 100 of about 43,621 (186)
OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta +4 more
wiley +1 more source
Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients
In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs +10 more
wiley +1 more source
ABSTRACT Background and Aim The incidence of ulcerative colitis (UC) has been increasing in Asia. Comprehensive data on the long‐term course of moderate‐to‐severe UC remain scarce. This study investigated the clinical outcomes and factors associated with a disabling disease course in Korean patients with moderate‐to‐severe UC.
Byong Duk Ye +14 more
wiley +1 more source
NEMO‐NDAS: Case Report and Review of the Literature
ABSTRACT NEMO‐deleted exon 5 autoinflammatory syndrome (NEMO‐NDAS) is the result of a gain‐of‐function IKBKG pathogenic variant leading to dysregulated NF‐κB signaling and systemic inflammation. We present a case of NEMO‐NDAS in a 2‐year‐old female presenting with recurrent fevers, subcutaneous nodules, lymphadenopathy, and splenomegaly.
Angela Yang +5 more
wiley +1 more source
Research progress on tofacitinib in the treatment of chronic actinic dermatitis
Chronic actinic dermatitis (CAD) is a group of immune-mediated diseases characterized by photosensitivity. Tofacitinib, a Janus kinase (JAK) 1/3 inhibitor, is currently the most extensively reported and widely used JAK inhibitor for the treatment of CAD.
WU Hui +5 more
doaj +1 more source
ABSTRACT Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic ...
Daphne M. Cheung +5 more
wiley +1 more source
Antibiotic‐mediated immune modulation in periodontitis
Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez +6 more
wiley +1 more source
The role of neutrophils in the pathophysiology of inflammatory bowel diseases
Abstract Objectives Inflammatory bowel disease (IBD) encompasses a spectrum of chronic disorders of the gastrointestinal tract, with a potential bidirectional relationship with periodontitis. Neutrophils are key regulators of immune‐inflammatory responses and play a major role in both diseases.
Joao Paulo Steffens +8 more
wiley +1 more source
Background Treatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents.
Qing Liu +11 more
doaj +1 more source
Sex Differences in Medication Discontinuation in Axial Spondyloarthritis
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall +9 more
wiley +1 more source

